Work

Low Levels of Neurologic Toxicity with Retained Anti-Lymphoma Activity in a Phase I Clinical Trial of T Cells Expressing a Novel Anti-CD19 CAR

Year: 2018

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2018-99-113731

Authors: Jennifer Brudno, Steven Hartman, Norris Lam, David F. Stroncek, John M. Rossi, Yueh-wei Shen, Allen Xue, Adrian Bot, Jennifer A Kanakry, Steven Z. Pavletic, Lekha Mikkilineni, Mark Roschewski, Robert M. Dean, Jeremy J. Rose, Rashmika Patel, Brenna Hansen, Steve A. Rosenberg, Ronald E. Gress, James N. Kochenderfer

Institutions: National Institutes of Health, National Cancer Institute, National Institutes of Health Clinical Center, Kite (United States), Center for Cancer Research, Cleveland Clinic

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2898813488

Cites:

Cited by: 8

Related to: 10